Skip to main content

Advertisement

SpringerLink
Log in

Bone metastases in breast cancer

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Patients with advanced breast cancer who develop bone metastases suffer from longterm skeletal morbidity. Complications of bone metastases include pain, pathologic fractures, and spinal cord compression, which have a significant impact on the quality of life of patients. Treatment options for patients with bone metastases include surgery, radiation, and analgesics to reduce bone pain and to prevent or repair fractures. Intravenous bisphosphonates can delay the onset of bone metastasis and reduce the percentage of patients who experience skeletal complications of bone metastasis, thus reducing skeletal morbidity. For the past 6 years, pamidronate disodium (90 mg administered by 2-hour intravenous infusion) has been the treatment of choice for the prevention of skeletal complications of bone metastases in patients with breast cancer. However, a more potent bisphosphonate, zoledronic acid (4 mg administered by 15-minute intravenous infusion), was approved for use and has improved efficacy in patients with bone metastases. Because of the increased efficacy and more convenient infusion time, zoledronic acid may become the new standard of care for the treatment and prevention of skeletal complications secondary to bone metastases in patients with breast cancer. Phase III clinical trials have shown that patients with an existing skeletal complication are more likely to develop subsequent complications compared with patients who have not experienced a complication. Therefore, zoledronic acid therapy should be initiated when the patient is diagnosed with bone metastasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Greenlee RT, Hill-Harmon MB, Murray T, et al.: Cancer statistics, 2001. CA Cancer J Clin 2001, 51:15–36. [Published erratum appears in CA Cancer J Clin 2001, 51:144.]

    Article  PubMed  CAS  Google Scholar 

  2. Ries LAG, Eisner MP, Kosary CL, et al.: SEER Cancer Statistics Review, 1973–1999. http://seer.cancer.gov/ csr/1973_1999/. Accessed October 16, 2002.

  3. Coleman RE: Skeletal complications of malignancy. Cancer 1997, 80(Suppl 8):1588–1594.

    Article  PubMed  CAS  Google Scholar 

  4. Mercadante S: Malignant bone pain: pathophysiology and treatment. Pain 1997, 69:1–18.

    Article  PubMed  CAS  Google Scholar 

  5. Theriault RL, Lipton A, Hortobagyi GN, et al.: Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999, 17:846–854. The placebo-controlled phase III study demonstrated the efficacy of pamidronate in reducing pain and skeletal complications in patients with breast cancer and metastatic bone disease and osteolytic lesions who were receiving hormonal therapy.

    PubMed  CAS  Google Scholar 

  6. Lipton A, Theriault RL, Hortobagyi GN, et al.: Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000, 88:1082–1090. A follow-up and combined analysis of protocols 18 and 19 [5,10] that established the long-term safety and efficacy of pamidronate in patients with breast cancer.

    Article  PubMed  CAS  Google Scholar 

  7. Serafini AN: Therapy of metastatic bone pain. J Nucl Med 2001, 42:895–906.

    PubMed  CAS  Google Scholar 

  8. Hortobagyi GN: Novel approaches to the management of bone metastases in patients with breast cancer. Semin Oncol 2002, 29(Suppl 11):134–144.

    Article  PubMed  CAS  Google Scholar 

  9. Rodan GA, Fleisch HA: Bisphosphonates: mechanisms of action. J Clin Invest 1996, 97:2692–2696.

    Article  PubMed  CAS  Google Scholar 

  10. Hortobagyi GN, Theriault RL, Porter L, et al.: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996, 335:1785–1791. The placebo-controlled phase III study was the first to demonstrate the efficacy of pamidronate in reducing pain and skeletal complications in patients with breast cancer and osteolytic metastatic bone lesions who were receiving chemotherapy.

    Article  PubMed  CAS  Google Scholar 

  11. Hortobagyi GN, Theriault RL, Lipton A, et al.: Longterm prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998, 16:2038–2044. A follow-up to protocol 19 that established the long-term efficacy and safety of pamidronate in patients with breast cancer who are receiving chemotherapy.

    PubMed  CAS  Google Scholar 

  12. Berenson JR, Lichtenstein A, Porter L, et al.: Longterm pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998, 16:593–602.

    PubMed  CAS  Google Scholar 

  13. Berenson JR, Lichtenstein A, Porter L, et al.: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996, 334:488–493.

    Article  PubMed  CAS  Google Scholar 

  14. Aredia [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2002.

  15. Hillner BE, Weeks JC, Desch CE, et al.: Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 2000, 18:72–79.

    PubMed  CAS  Google Scholar 

  16. Hillner BE, Ingle JN, Berenson JR, et al.: American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol 2000, 18:1378–1391.

    PubMed  CAS  Google Scholar 

  17. Coleman RE, Rosen LS, Gordon D, et al.: Zoledronic acid (4 mg) significantly reduces the relative risk of developing a skeletal-related event compared with pamidronate (90 mg) in patients with breast cancer and bone metastasis [abstract]. Paper presented at the 25th Annual San Antonio Breast Cancer Symposium. San Antonio, TX; December 11–14, 2002.

  18. Rosen L, Gordon DH, Dugan W Jr, et al.: Zoledronic acid (4 mg) is more effective than pamidronate (90 mg) for treating bone metastases in breast cancer patients with at least one osteolytic lesion [abstract]. Paper presented at the 27th European Society for Medical Oncology Congress. Nice, France; October 18–22, 2002.

  19. Major P, Lortholary A, Hon J, et al.: Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001, 19:558–567.

    PubMed  CAS  Google Scholar 

  20. Rosen LS, Gordon D, Kaminski M, et al.: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, doubleblind, comparative trial. Cancer J 2001, 7:377–387. The pivotal trial established the efficacy of zoledronic acid for the treatment of bone metastases in patients with breast cancer and multiple myeloma. Zoledronic acid was shown to be as effective as pamidronate in reducing pain and skeletal complications in patients with multiple myeloma or advanced breast cancer and bone metastases with chemotherapy or hormonal therapy. Unlike the trials of pamidronate, which enrolled only patients with breast cancer and osteolytic lesions, this trial enrolled patients with breast cancer and osteolytic, mixed, or osteoblastic lesions. Zoledronic acid was demonstrated to be as safe as pamidronate.

    PubMed  CAS  Google Scholar 

  21. McCloskey EV, Dunn JA, Kanis JA, et al.: Long-term follow-up of a prospective, double-blind, placebocontrolled randomized trial of clodronate in multiple myeloma. Br J Haematol 2001, 113:1035–1043.

    Article  PubMed  CAS  Google Scholar 

  22. Saad F, Lipton A, Colombo-Berra A, et al.: ZOMETA (zoledronic acid) is effective in preventing and delaying skeletal events in patients with bone metastases secondary to urologic malignancies [abstract]. Paper presented at the Quebec Urological Association Meeting. Montreal, Quebec, Canada; November 15–17, 2002.

  23. Diel IJ, Solomayer EF, Costa SD, et al.: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998, 339:357–363.

    Article  PubMed  CAS  Google Scholar 

  24. Saarto T, Blomqvist C, Virkkunen P, et al.: Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 2001, 19:10–17.

    PubMed  CAS  Google Scholar 

  25. Powles T, Paterson S, Kanis JA, et al.: Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002, 20:3219–3224.

    Article  PubMed  CAS  Google Scholar 

  26. ZOMETA [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2002.

  27. DesHarnais Castel L, Bajwa K, Markle JP, et al.: A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. Support Care Cancer 2001, 9:545–551.

    Article  Google Scholar 

  28. Viereck V, Emons G, Lauck V, et al.: Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 2002, 291:680–686.

    Article  PubMed  CAS  Google Scholar 

  29. Lacey DL, Timms E, Tan HL, et al.: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165–176.

    Article  PubMed  CAS  Google Scholar 

  30. Morony S, Capparelli C, Sarosi I, et al.: Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 2001, 61:4432–4436.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pennsylvania State University, Milton S. Hershey Medical Center, 500 University Drive, 17033, Hershey, PA, USA

    Allan Lipton MD

Authors
  1. Allan Lipton MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lipton, A. Bone metastases in breast cancer. Curr. Treat. Options in Oncol. 4, 151–158 (2003). https://doi.org/10.1007/s11864-003-0016-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-003-0016-9

Keywords

Search

Navigation